Montreal, November 29, 2019 – The Chairman of the Scientific Advisory Board, Daniel Hétu, and the President and CEO of CQDM, Diane Gosselin, are pleased to announce the appointment of two new members to CQDM’s governance. Bernard Massie, former Director General, Human Health Therapeutics at the NRC, and Cameron Black, Executive Vice President, Discovery at Repare Therapeutics…
The project led by Michel Bouvier and Domain Therapeutics with the support of CQDM is awarded the RSRI Recognition Award at the ADRIQ Innovation Prize Gala Montreal, November 22, 2019 – CQDM is proud to announce that the project led by Michel Bouvier from the Institute for Research in Immunology and Cancer (IRIC) of the Université de…
Zealand Pharma’s acquisition of Encycle Therapeutics highlights the impact of CQDM’s early support on Canadian biotech company creation and success. Montreal, November 11th, 2019 – CQDM commends Encycle Therapeutics for their acquisition by Zealand Pharma (NASDAQ: ZEAL)[1]. CQDM is proud to have supported Encycle Therapeutics and its technology platform from the very beginning in partnership…
CQDM, the Canadian Cancer Society and Theratechnologies grant $1.7M to UQAM for the development of a new therapy targeting the most aggressive form of breast cancer Montreal, October 4, 2019. – CQDM, in partnership with the Canadian Cancer Society (CCS) and Theratechnologies, is proud to announce that it will be granting $1.7M to Université du…
New appointments to CQDM’s Board of Directors and Scientific Advisory Board Montreal, September 23, 2019 – The chairman of the Board of Directors, Richard Fajzel, and Diane Gosselin, President and CEO of CQDM, are very pleased to announce the appointment of four new members overseeing CQDM’s governance. Daniel Hétu, Managing Director of Lumira Ventures, Sarah Jenna,…
PARTENAR-IA, a funding initiative to support public-private AI-based research projects ! DEADLINE: OCTOBER 15th, 2019 Montreal, August 20th, 2019 – The PARTENAR-IA initiative aims to accelerate the design and development of Artificial Intelligence (AI) technologies applicable in the biopharmaceutical sector by participating in the funding of collaborative research projects carried out in a Quebec public research…
The SynergiQc-International program is geared to support public/private research with partners outside the province of Quebec ! DEADLINE: OCTOBER 7th, 2019 Montreal, July 16th, 2019 – CQDM has launched the SynergiQc-International funding program that may cover up to 50% of R&D expenses incurred in Quebec as part of a public/private partnership in the biopharmaceutical field, up…
Amgen and Takeda join the Quantum Leap project led by CQDM and Feldan Therapeutics, to improve a novel intracellular delivery technology Philadelphia, June 4th, 2019 – CQDM is pleased to announce that following their recent enrollment in the consortium, Amgen and Takeda will be joining the syndicate of pharma companies to fund the Quantum Leap…
These highly innovative technologies will address unmet medical needs in cancer and diabetes Philadelphia, June 4th, 2019 – Thanks to a C$3.3M contribution from the MEI, and the participation of several partners, CQDM is proud to announce the funding of five collaborative research projects totaling C$15.5M. Headed by world-class experts in the field of cancer and diabetes,…
Montreal, June 1, 2019 – The Canadian Cancer Society (CCS), a leading breast cancer research funder, and CQDM, a Quebec research consortium whose mission is to fund the development of biopharmaceutical technologies and drugs, are proud to announce that nearly $10 million will be invested to fund three breast cancer research projects over the next…